

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WCH 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.350

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2019 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 867** Changing the wolf from outside: how microbiota trigger systemic lupus erythematosus
I Peene, D Elewaut

Heroes and pillars of rheumatology

- 870** Henry G Kunkel and Rheumatoid Factor
E M Tan

Review

- 872** Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018
K L Winthrop, M E Weinblatt, M K Crow, G R Burmester, P J Mease, A K So, V Bykerk, R F Van Vollenhoven, M Dougados, J Kay, X Mariette, J Sieper, F Melchers, B N Cronstein, E Shevach, F C Breedfeld, J Kalden, J S Smolen, D E Furst

Recommendation

- 879** Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective
J Damoiseaux, L E C Andrade, O G Carballo, K Conrad, P L C Francescantonio, M J Fritzler, I Garcia de la Torre, M Herold, W Klotz, W d M Cruvinel, T Mimori, C von Muhlen, M Satoh, E K Chan

Rheumatoid arthritis

- 890** Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
Y Tanaka, B Fautrel, E C Keystone, R A Ortmann, L Xie, B Zhu, M Issa, H Patel, C L Gaich, S de Bono, T P Rooney, P C Taylor

- 899** Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
T Takeuchi, Y Tanaka, S Soen, H Yamanaka, T Yoneda, S Tanaka, T Niita, N Okubo, H K Genant, D van der Heijde

- 908** Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification
A S B Kampstra, J S Dekkers, M Volkov, A L Dorjée, L Hafkenscheid, A C Kempers, M van Delft, T Kissel, S Reijm, G M C Janssen, P A van Veelen, H Bang, T W J Huizinga, L A Trouw, D van der Woude, R E M Toes

- 917** Valine 11 and phenylalanine 13 have a greater impact on the T-cell response to citrullinated peptides than the 70–74 shared epitope of the DRB1 molecule in macaques
S Bitoun, P Roques, B Maillere, R Le Grand, X Mariette

Spondyloarthritis

- 922** Aortic-vertebral interaction in ankylosing spondylitis: syndesmophyte development at the juxta-aortic vertebral rim
S Tan, A Dasgupta, J A Flynn, M M Ward

- 929** Identification of myeloid cells in the human enthesis as the main source of local IL-23 production
C Bridgewood, A Watad, T Russell, T M Palmer, H Marzo-Ortega, A Khan, P A Millner, R Dunsmuir, A Rao, P Loughenbury, M Wittmann, R J Cuthbert, D G McGonagle

Systemic lupus erythematosus

- 934** Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes
M Barraclough, S McKie, B Parker, A Jackson, P Pemberton, R Elliott, I N Bruce

- 941** Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan
T-H Li, C-C Lai, W-H Wang, W-S Chen, Y-P Tsao, C-Y Tsai, Y-S Chang

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 947** Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal



D Azzouz, A Omarbekova, A Heguy, D Schwudke, N Gisch, B H Rovin, R Caricchio, J P Buyon, A V Alekseyenko, C J Silverman

- 957** Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus



S Rahman, D Sagar, R N Hanna, Y L Lightfoot, P Mistry, C K Smith, Z Manna, S Hasni, R M Siegel, M A Sanjuan, R Kolbeck, M J Kaplan, K A Casey

Sjögren's syndrome

- 967** Video clip assessment of a salivary gland ultrasound scoring system in Sjögren's syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise

S Jousse-Joulin, M A D'Agostino, C Nicolas, E Naredo, S Ohrndorf, M Backhaus, G Tamborini, I Chary-Valckenaere, L Terslev, A Iagnocco, P Collado, C Hernández-Díaz, F Gandjbakhch, W A Schmidt, G Filippou, C Dejaco, M H Sradner, M A Monada, A Hočevnar, S Chrysidis, G El Mardenly, J J de Agustín, R Thiele, D K MacCarter, S Finzel, P Hanova, A Zabotti, C Glaser, Z Alavi, D S Hammenfors, F Gatineau, G AW Bruyn

- 974** Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome

G Wiczorek, M Bigaud, S Pfister, M Ceci, K McMichael, C Afatsawo, M Hamburger, C Texier, M Henry, C Cojean, M Erard, N Mamber, J S Rush

Systemic sclerosis

- 979** Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

M Elhai, M Boukaya, O Distler, V Smith, M Matucci-Cerinic, J J Alegre Sancho, M-E Truchetet, Y Braun-Moscovici, F Iannone, P I Novikov, A Lescoat, E Siegert, I Castellví, P Airó, S Vettori, E De Langhe, E Hachulla, A Erler, L Ananieva, M Krusche, F J López-Longo, J H W Distler, N Hunzelmann, A-M Hoffmann-Vold, V Ricciari, V M Hsu, M R Pozzi, C Ancuta, E Rosato, C Mihai, M Kuwana, L A Saketko, C Chizzolini, R Hesselstrand, S Ullman, S Yavuz, S Rednic, C Caimmi, C Bloch-Queyrat, Y Allanore, for EUSTAR network

Myositis

- 988** Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis

S Sabbagh, I Pinal-Fernandez, T Kishi, I N Targoff, F W Miller, L G Rider, A L Mammen

- 996** Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups



S Rothwell, H Chinoy, J A Lamb, F W Miller, L G Rider, L R Wedderburn, N J McHugh, A L Mammen, Z E Betteridge, S L Tansley, J Bowes, J Vencovský, C T Deakin, K Dankó, L Vidya, A Selva-O'Callaghan, L M Pachman, A M Reed, Ø Molberg, O Benveniste, P R Mathiesen, T R D J Radstake, A Doria, J de Bleeker, A T Lee, M G Hanna, P M Machado, W E Ollier, P K Gregersen, L Padyukov, T P O'Hanlon, R G Cooper, I E Lundberg, on behalf of Myositis Genetics Consortium (MYOGEN)

Letters

- 1003** Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease

M Haroon, P Gallagher, O FitzGerald

- 1004** Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study

S Sciascia, J Yazdany, M Dall'Era, R Fenoglio, M Radin, I Aggarwal, M J Cuadrado, K Schreiber, A Barreca, M Papotti, D Roccatello

- 1006** Established organ damage reduces belimumab efficacy in systemic lupus erythematosus

I Parodis, A Gomez, S Emamikia, K Chatzidionysiou

- 1007** Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study

M Scherlinger, C Carcaud, M-E Truchetet, T Barnette, P Duffau, L Couzi, J Seneschal, P Blanco, E Lazaro, C Richez

- 1010** Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort



A Mendel, S B Bernatsky, J G Hanly, M B Urowitz, A E Clarke, J Romero-Diaz, C Gordon, S-C Bae, D J Wallace, J T Merrill, J P Buyon, D A Isenberg, A Rahman, E M Ginzler, M Petri, M A Dooley, P R Fortin, D D Gladman, K Steinsson, R Ramsey-Goldman, M A Khamashta, C Aranow, M Mackay, G S Alarcón, S Manzi, O Nived, A Jönsen, A A Zoma, R F van Vollenhoven, M Ramos-Casals, G Ruiz-Irastorza, S Lim, K C Kalunian, M Inanc, D L Kamen, C A Peschken, S Jacobsen, A Askanase, J Sanchez-Guerrero, I N Bruce, N Costedoat-Chalumeau, É Vinet

1012 Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses

C T Berger, B Rebholz-Chaves, M Recher, T Manigold, T Daikeler

Electronic pages

e61 To DAPSA or not to DAPSA? That is not the question

M M Schoels, J S Smolen, D Aletaha

e62 Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels *et al*

L J J van Mens, M G H van de Sande, A W R van Kuijk, D L P Baeten, L C Coates

e63 Infrapatellar fat pad resection during total knee arthroplasty: yet another reason for?

T J Ryan

e64 Response to: 'Infrapatellar fat pad resection during total knee replacement: yet another reason?' by Ryan

Z Zhu, W Han, G Ruan, S Zheng, C Ding

e65 Serum complement factor C5a in IgG₄-related disease

S Fukui, Y Fujita, T Origuchi, T Maeda, A Kawakami

e66 Response to: 'Serum complement factor C5a in IgG₄-related disease' by Fukui *et al*

H Umehara, M Kawano

e67 Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1

J-M Michot, M Fusellier, S Champiat, C Velter, C Baldini, A-L Voisin, F-X Danlos, Y E Dakdouki, M Annereau, X Mariette, C Robert, K Cherif, A Marabelle, C Mateus, O Lambotte

e68 Checkpoint inhibitor-associated immune arthritis

L Arnaud, B Lebrun-Vignes, J-E Salem

e69 Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot *et al* and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud *et al*

M Kostine, C Richez, T Schaeverbeke, on behalf of the FHU-ACRONIM

e70 Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor

K K Chan, A R Bass

e71 Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass

M Kostine, L Dousset, T Schaeverbeke, on behalf of the FHU-ACRONIM

e72 Tofacitinib in steroid-dependent relapsing polychondritis

A D Meshkov, P I Novikov, E V Zhilyaev, I D J Ilevsky, S V Moiseev

e73 Correction: ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study